1
|
Hosseinnezhad-Lazarjani E, Doosti A, Sharifzadeh A. Novel csuC-DNA nanovaccine based on chitosan candidate vaccine against infection with Acinetobacter baumannii. Vaccine 2023; 41:2170-2183. [PMID: 36841724 DOI: 10.1016/j.vaccine.2023.02.046] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2022] [Revised: 02/10/2023] [Accepted: 02/13/2023] [Indexed: 02/27/2023]
Abstract
BACKGROUND Generating vaccines is a promising and effective method for stopping the spread of Acinetobacter baumannii (A. baumannii) infections that are becoming more and more drug-resistant (MDR). Developing a DNA vaccine and testing its efficacy and protective effects in BALB/c mice were the goals of this research. METHODS We examined the genomes of 35 different strains of A. baumannii using the Vaxign online program, and we selected outer membrane and secreted proteins as potential vaccine candidates. Next, the proteins' immunogenicity, antigenic features, physical and chemical characteristics, and B and MHCI/II cell epitope concentrations were assessed. The DNA vaccine was synthesized. Then, to generate CS-DNA nanoparticles, the DNA vaccine was e encapsulated by chitosan (CS) nanoparticles (NPs). BALB/c mice were used to assess the vaccine's immunogenicity and immunoprotective effectiveness. RESULTS CS-DNA NPs were nontoxic, positively charged (4.39 mV), and small (mean size of 285-350 nm) with ostensibly spherical shapes. It was possible to establish a continuously slow release profile and a high entrapment efficiency (78.12 %). CS-DNA vaccinated BALB/c mice elicited greater levels of csuC-specific IgG in plasma and IFN-γ in splenocyte lysate compared with non-encapsulated DNA vaccine. In addition, BALB/c mice immunized with CS-DNA nanovaccine showed decreased lung damage and bacterial loads in the lung and blood, as well as significant immunity (87.5 %) versus acute fatal intratracheal A. baumannii challenge. CONCLUSION In conclusion, acute fatal intratracheal A. baumannii exposure was prevented by CS-DNA NPs that induced specific IgG antibodies, Th1 cellular immunity, and other protective mechanisms. Our findings show that this nanovaccine is a promising contender for stopping the spread of A. baumannii infection.
Collapse
Affiliation(s)
| | - Abbas Doosti
- Biotechnology Research Center, Shahrekord Branch, Islamic Azad University, Shahrekord, Iran
| | - Ali Sharifzadeh
- Department of Microbiology, Faculty of Veterinary Medicine, Shahrekord Branch, Islamic Azad University, Shahrekord, Iran
| |
Collapse
|
2
|
Lang CH. IMPORTANCE OF THE INNATE IMMUNE RESPONSE IN SKELETAL MUSCLE TO SEPSIS-INDUCED ALTERATIONS IN PROTEIN BALANCE. Shock 2023; 59:214-223. [PMID: 36730901 PMCID: PMC9957944 DOI: 10.1097/shk.0000000000002029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
ABSTRACT There is growing appreciation that skeletal muscle is a fully functional component of the body's innate immune system with the potential to actively participate in the host response to invading bacteria as opposed to being a passive target. In this regard, skeletal muscle in general and myocytes specifically possess an afferent limb that recognizes a wide variety of host pathogens via their interaction with multiple classes of cell membrane-bound and intracellular receptors, including toll-like receptors, cytokine receptors, NOD-like receptors, and the NLRP inflammasome. The efferent limb of the innate immune system in muscle is equally robust and with an increased synthesis and secretion of a variety of myocyte-derived cytokines (i.e., myokines), including TNF-α, IL-1, IL-6, and NO as well as multiple chemokines in response to appropriate stimulation. Herein, the current narrative review focuses primarily on the immune response of myocytes per se as opposed to other cell types within whole muscle. Moreover, because there are important differences, this review focuses specifically on systemic infection and inflammation as opposed to the response of muscle to direct injury and various types of muscular dystrophies. To date, however, there are few definitive muscle-specific studies that are necessary to directly address the relative importance of muscle-derived immune activation as a contributor to either the systemic immune response or the local immune microenvironment within muscle during sepsis and the resultant downstream metabolic disturbances.
Collapse
Affiliation(s)
- Charles H Lang
- Cellular and Molecular Physiology, Penn State College of Medicine, Hershey, Pennsylvania
| |
Collapse
|
3
|
Bomfim CCB, Fisher L, Amaral EP, Mittereder L, McCann K, Correa AAS, Namasivayam S, Swamydas M, Moayeri M, Weiss JM, Chari R, McVicar DW, Costa DL, D’Império Lima MR, Sher A. Mycobacterium tuberculosis Induces Irg1 in Murine Macrophages by a Pathway Involving Both TLR-2 and STING/IFNAR Signaling and Requiring Bacterial Phagocytosis. Front Cell Infect Microbiol 2022; 12:862582. [PMID: 35586249 PMCID: PMC9109611 DOI: 10.3389/fcimb.2022.862582] [Citation(s) in RCA: 20] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2022] [Accepted: 04/01/2022] [Indexed: 11/13/2022] Open
Abstract
Irg1 is an enzyme that generates itaconate, a metabolite that plays a key role in the regulation of inflammatory responses. Previous studies have implicated Irg1 as an important mediator in preventing excessive inflammation and tissue damage in Mycobacterium tuberculosis (Mtb) infection. Here, we investigated the pattern recognition receptors and signaling pathways by which Mtb triggers Irg1 gene expression by comparing the responses of control and genetically deficient BMDMs. Using this approach, we demonstrated partial roles for TLR-2 (but not TLR-4 or -9), MyD88 and NFκB signaling in Irg1 induction by Mtb bacilli. In addition, drug inhibition studies revealed major requirements for phagocytosis and endosomal acidification in Irg1 expression triggered by Mtb but not LPS or PAM3CSK4. Importantly, the Mtb-induced Irg1 response was highly dependent on the presence of the bacterial ESX-1 secretion system, as well as host STING and Type I IFN receptor (IFNAR) signaling with Type II IFN (IFN-γ) signaling playing only a minimal role. Based on these findings we hypothesize that Mtb induces Irg1 expression in macrophages via the combination of two independent triggers both dependent on bacterial phagocytosis: 1) a major signal stimulated by phagocytized Mtb products released by an ESX-1-dependent mechanism into the cytosol where they activate the STING pathway leading to Type I-IFN production, and 2) a secondary TLR-2, MyD88 and NFκB dependent signal that enhances Irg1 production independently of Type I IFN induction.
Collapse
Affiliation(s)
- Caio C. B. Bomfim
- Department of Immunology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil
- Laboratory of Parasitic Diseases - National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States
| | - Logan Fisher
- Laboratory of Parasitic Diseases - National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States
| | - Eduardo P. Amaral
- Laboratory of Parasitic Diseases - National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States
| | - Lara Mittereder
- Laboratory of Parasitic Diseases - National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States
| | - Katelyn McCann
- Laboratory of Clinical Immunology and Microbiology - National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States
| | - André A. S. Correa
- Department of Biochemistry and Immunology - Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil
- Graduate Program in Basic and Applied Immunology - Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil
| | - Sivaranjani Namasivayam
- Laboratory of Parasitic Diseases - National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States
| | - Muthulekha Swamydas
- Laboratory of Clinical Immunology and Microbiology - National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States
| | - Mahtab Moayeri
- Department of Immunology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil
| | - Jonathan M. Weiss
- Laboratory of Cancer Immunometabolism, Center for Cancer Research, National Cancer Institute, Frederick, MD, United States
| | - Raj Chari
- Laboratory Animal Sciences Program, Frederick National Laboratory for Cancer Research, Frederick, MD, United States
| | - Daniel W. McVicar
- Laboratory of Cancer Immunometabolism, Center for Cancer Research, National Cancer Institute, Frederick, MD, United States
| | - Diego L. Costa
- Department of Biochemistry and Immunology - Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil
- Graduate Program in Basic and Applied Immunology - Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil
| | - Maria R. D’Império Lima
- Department of Immunology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil
| | - Alan Sher
- Laboratory of Parasitic Diseases - National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States
| |
Collapse
|
4
|
Guzelj S, Nabergoj S, Gobec M, Pajk S, Klančič V, Slütter B, Frkanec R, Štimac A, Šket P, Plavec J, Mlinarič-Raščan I, Jakopin Ž. Structural Fine-Tuning of Desmuramylpeptide NOD2 Agonists Defines Their In Vivo Adjuvant Activity. J Med Chem 2021; 64:7809-7838. [PMID: 34043358 PMCID: PMC8279416 DOI: 10.1021/acs.jmedchem.1c00644] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
![]()
We
report on the design, synthesis, and biological evaluation of
a series of nucleotide-binding oligomerization-domain-containing protein
2 (NOD2) desmuramylpeptide agonists with improved in vitro and in vivo adjuvant properties. We identified
two promising compounds: 68, a potent nanomolar in vitro NOD2 agonist, and the more lipophilic 75, which shows superior adjuvant activity in vivo. Both compounds had immunostimulatory effects on peripheral blood
mononuclear cells at the protein and transcriptional levels, and augmented
dendritic-cell-mediated activation of T cells, while 75 additionally enhanced the cytotoxic activity of peripheral blood
mononuclear cells against malignant cells. The C18 lipophilic
tail of 75 is identified as a pivotal structural element
that confers in vivo adjuvant activity in conjunction
with a liposomal delivery system. Accordingly, liposome-encapsulated 75 showed promising adjuvant activity in mice, surpassing
that of muramyl dipeptide, while achieving a more balanced Th1/Th2
immune response, thus highlighting its potential as a vaccine adjuvant.
Collapse
Affiliation(s)
- Samo Guzelj
- Faculty of Pharmacy, University of Ljubljana, SI-1000 Ljubljana, Slovenia
| | - Sanja Nabergoj
- Faculty of Pharmacy, University of Ljubljana, SI-1000 Ljubljana, Slovenia
| | - Martina Gobec
- Faculty of Pharmacy, University of Ljubljana, SI-1000 Ljubljana, Slovenia
| | - Stane Pajk
- Faculty of Pharmacy, University of Ljubljana, SI-1000 Ljubljana, Slovenia
| | - Veronika Klančič
- Faculty of Pharmacy, University of Ljubljana, SI-1000 Ljubljana, Slovenia
| | - Bram Slütter
- Div. BioTherapeutics, Leiden Academic Centre for Drug Research, Leiden University, 2333 CC Leiden, The Netherlands
| | - Ruža Frkanec
- Centre for Research and Knowledge Transfer in Biotechnology, University of Zagreb, 10000 Zagreb, Croatia
| | - Adela Štimac
- Centre for Research and Knowledge Transfer in Biotechnology, University of Zagreb, 10000 Zagreb, Croatia
| | - Primož Šket
- Slovenian NMR Centre, National Institute of Chemistry, SI-1000 Ljubljana, Slovenia
| | - Janez Plavec
- Slovenian NMR Centre, National Institute of Chemistry, SI-1000 Ljubljana, Slovenia
| | | | - Žiga Jakopin
- Faculty of Pharmacy, University of Ljubljana, SI-1000 Ljubljana, Slovenia
| |
Collapse
|
5
|
Harris PE, Brasel T, Massey C, Herst CV, Burkholz S, Lloyd P, Blankenberg T, Bey TM, Carback R, Hodge T, Ciotlos S, Wang L, Comer JE, Rubsamen RM. A Synthetic Peptide CTL Vaccine Targeting Nucleocapsid Confers Protection from SARS-CoV-2 Challenge in Rhesus Macaques. Vaccines (Basel) 2021; 9:520. [PMID: 34070152 PMCID: PMC8158516 DOI: 10.3390/vaccines9050520] [Citation(s) in RCA: 18] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2021] [Revised: 05/10/2021] [Accepted: 05/13/2021] [Indexed: 12/21/2022] Open
Abstract
BACKGROUND Persistent transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has given rise to a COVID-19 pandemic. Several vaccines, conceived in 2020, that evoke protective spike antibody responses are being deployed in mass public health vaccination programs. Recent data suggests, however, that as sequence variation in the spike genome accumulates, some vaccines may lose efficacy. METHODS Using a macaque model of SARS-CoV-2 infection, we tested the efficacy of a peptide-based vaccine targeting MHC class I epitopes on the SARS-CoV-2 nucleocapsid protein. We administered biodegradable microspheres with synthetic peptides and adjuvants to rhesus macaques. Unvaccinated control and vaccinated macaques were challenged with 1 × 108 TCID50 units of SARS-CoV-2, followed by assessment of clinical symptoms and viral load, chest radiographs, and sampling of peripheral blood and bronchoalveolar lavage (BAL) fluid for downstream analysis. RESULTS Vaccinated animals were free of pneumonia-like infiltrates characteristic of SARS-CoV-2 infection and presented with lower viral loads relative to controls. Gene expression in cells collected from BAL samples of vaccinated macaques revealed a unique signature associated with enhanced development of adaptive immune responses relative to control macaques. CONCLUSIONS We demonstrate that a room temperature stable peptide vaccine based on known immunogenic HLA class I bound CTL epitopes from the nucleocapsid protein can provide protection against SARS-CoV-2 infection in nonhuman primates.
Collapse
Affiliation(s)
- Paul E. Harris
- Department of Medicine, Columbia University, P&S 10-502, 650 West 168th Street, New York, NY 10032, USA;
| | - Trevor Brasel
- Department of Microbiology & Immunology, University of Texas Medical Branch, 301 University Blvd., Galveston, TX 77555, USA; (T.B.); (C.M.)
| | - Christopher Massey
- Department of Microbiology & Immunology, University of Texas Medical Branch, 301 University Blvd., Galveston, TX 77555, USA; (T.B.); (C.M.)
| | - C. V. Herst
- Flow Pharma Inc., 4829 Galaxy Parkway, Suite K, Warrensville Heights, OH 44128, USA; (C.V.H.); (S.B.); (P.L.); (T.B.); (R.C.); (T.H.); (S.C.); (L.W.)
| | - Scott Burkholz
- Flow Pharma Inc., 4829 Galaxy Parkway, Suite K, Warrensville Heights, OH 44128, USA; (C.V.H.); (S.B.); (P.L.); (T.B.); (R.C.); (T.H.); (S.C.); (L.W.)
| | - Peter Lloyd
- Flow Pharma Inc., 4829 Galaxy Parkway, Suite K, Warrensville Heights, OH 44128, USA; (C.V.H.); (S.B.); (P.L.); (T.B.); (R.C.); (T.H.); (S.C.); (L.W.)
| | - Tikoes Blankenberg
- Flow Pharma Inc., 4829 Galaxy Parkway, Suite K, Warrensville Heights, OH 44128, USA; (C.V.H.); (S.B.); (P.L.); (T.B.); (R.C.); (T.H.); (S.C.); (L.W.)
- Dignity Health Mercy Medical Center, Redding, CA 96001, USA;
| | - Thomas M. Bey
- Dignity Health Mercy Medical Center, Redding, CA 96001, USA;
| | - Richard Carback
- Flow Pharma Inc., 4829 Galaxy Parkway, Suite K, Warrensville Heights, OH 44128, USA; (C.V.H.); (S.B.); (P.L.); (T.B.); (R.C.); (T.H.); (S.C.); (L.W.)
| | - Thomas Hodge
- Flow Pharma Inc., 4829 Galaxy Parkway, Suite K, Warrensville Heights, OH 44128, USA; (C.V.H.); (S.B.); (P.L.); (T.B.); (R.C.); (T.H.); (S.C.); (L.W.)
| | - Serban Ciotlos
- Flow Pharma Inc., 4829 Galaxy Parkway, Suite K, Warrensville Heights, OH 44128, USA; (C.V.H.); (S.B.); (P.L.); (T.B.); (R.C.); (T.H.); (S.C.); (L.W.)
| | - Lu Wang
- Flow Pharma Inc., 4829 Galaxy Parkway, Suite K, Warrensville Heights, OH 44128, USA; (C.V.H.); (S.B.); (P.L.); (T.B.); (R.C.); (T.H.); (S.C.); (L.W.)
| | - Jason E. Comer
- Department of Microbiology & Immunology, University of Texas Medical Branch, 301 University Blvd., Galveston, TX 77555, USA; (T.B.); (C.M.)
| | - Reid M. Rubsamen
- Flow Pharma Inc., 4829 Galaxy Parkway, Suite K, Warrensville Heights, OH 44128, USA; (C.V.H.); (S.B.); (P.L.); (T.B.); (R.C.); (T.H.); (S.C.); (L.W.)
- The Department of Anesthesiology and Perioperative Medicine, Case Western Reserve School of Medicine, Cleveland Medical Center, University Hospitals, Cleveland, OH 44106, USA
- Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, MA 96001, USA
| |
Collapse
|
6
|
Chansard A, Dubrulle N, Poujol de Molliens M, Falanga PB, Stephen T, Hasan M, van Zandbergen G, Aulner N, Shorte SL, David-Watine B. Unveiling Interindividual Variability of Human Fibroblast Innate Immune Response Using Robust Cell-Based Protocols. Front Immunol 2021; 11:569331. [PMID: 33505391 PMCID: PMC7829859 DOI: 10.3389/fimmu.2020.569331] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2020] [Accepted: 11/19/2020] [Indexed: 11/13/2022] Open
Abstract
The LabEx Milieu Interieur (MI) project is a clinical study centered on the detailed characterization of the baseline and induced immune responses in blood samples from 1,000 healthy donors. Analyses of these samples has lay ground for seminal studies on the genetic and environmental determinants of immunologic variance in a healthy cohort population. In the current study we developed in vitro methods enabling standardized quantification of MI-cohort-derived primary fibroblasts responses. Our results show that in vitro human donor cohort fibroblast responses to stimulation by different MAMPs analogs allows to characterize individual donor immune-phenotype variability. The results provide proof-of-concept foundation to a new experimental framework for such studies. A bio-bank of primary fibroblast lines was generated from 323 out of 1,000 healthy individuals selected from the MI-study cohort. To study inter-donor variability of innate immune response in primary human dermal fibroblasts we chose to measure the TLR3 and TLR4 response pathways, both receptors being expressed and previously studied in fibroblasts. We established high-throughput automation compatible methods for standardized primary fibroblast cell activation, using purified MAMPS analogs, poly I:C and LPS that stimulate TLR3 and TLR4 pathways respectively. These results were in turn compared with a stimulation method using infection by HSV-1 virus. Our "Add-only" protocol minimizes high-throughput automation system variability facilitating whole process automation from cell plating through stimulation to recovery of cell supernatants, and fluorescent labeling. Images were acquired automatically by high-throughput acquisition on an automated high-content imaging microscope. Under these methodological conditions standardized image acquisition provided for quantification of cellular responses allowing biological variability to be measured with low system noise and high biological signal fidelity. Optimal for automated analysis of immuno-phenotype of primary human cell responses our method and experimental framework as reported here is highly compatible to high-throughput screening protocols like those necessary for chemo-genomic screening. In context of primary fibroblasts derived from donors enrolled to the MI-clinical-study our results open the way to assert the utility of studying immune-phenotype characteristics relevant to a human clinical cohort.
Collapse
Affiliation(s)
- Audrey Chansard
- UTechS Photonic BioImaging, C2RT, Institut Pasteur, Paris, France
| | - Nelly Dubrulle
- UTechS Photonic BioImaging, C2RT, Institut Pasteur, Paris, France
| | | | - Pierre B Falanga
- UTechS Photonic BioImaging, C2RT, Institut Pasteur, Paris, France
| | - Tharshana Stephen
- UTechS Cytometry and Biomarkers, CRT, Institut Pasteur, Paris, France
| | - Milena Hasan
- UTechS Cytometry and Biomarkers, CRT, Institut Pasteur, Paris, France
| | - Ger van Zandbergen
- Division of Immunology, Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines, Langen, Germany
| | - Nathalie Aulner
- UTechS Photonic BioImaging, C2RT, Institut Pasteur, Paris, France
| | - Spencer L Shorte
- UTechS Photonic BioImaging, C2RT, Institut Pasteur, Paris, France.,Pasteur Joint International Research Unit Ai3D, Institut Pasteur Korea, Seongnam-si, South Korea
| | - Brigitte David-Watine
- UTechS Photonic BioImaging, C2RT, Institut Pasteur, Paris, France.,Unité INSERM U 1223, Institut Pasteur, Paris, France.,Unité Biologie et Génétique de la Paroi Bactérienne, Institut Pasteur, Paris, France.,CNRS UMR2001, Paris, France.,INSERM, Équipe Avenir, Paris, France
| |
Collapse
|
7
|
Noé A, Cargill TN, Nielsen CM, Russell AJC, Barnes E. The Application of Single-Cell RNA Sequencing in Vaccinology. J Immunol Res 2020; 2020:8624963. [PMID: 32802896 PMCID: PMC7411487 DOI: 10.1155/2020/8624963] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2020] [Accepted: 07/09/2020] [Indexed: 02/06/2023] Open
Abstract
Single-cell RNA sequencing allows highly detailed profiling of cellular immune responses from limited-volume samples, advancing prospects of a new era of systems immunology. The power of single-cell RNA sequencing offers various opportunities to decipher the immune response to infectious diseases and vaccines. Here, we describe the potential uses of single-cell RNA sequencing methods in prophylactic vaccine development, concentrating on infectious diseases including COVID-19. Using examples from several diseases, we review how single-cell RNA sequencing has been used to evaluate the immunological response to different vaccine platforms and regimens. By highlighting published and unpublished single-cell RNA sequencing studies relevant to vaccinology, we discuss some general considerations how the field could be enriched with the widespread adoption of this technology.
Collapse
MESH Headings
- Animals
- Betacoronavirus/immunology
- COVID-19
- Cell Line
- Clinical Trials as Topic
- Coronavirus Infections/epidemiology
- Coronavirus Infections/immunology
- Coronavirus Infections/prevention & control
- Coronavirus Infections/virology
- Disease Models, Animal
- Drug Evaluation, Preclinical
- Host-Pathogen Interactions/genetics
- Host-Pathogen Interactions/immunology
- Humans
- Immunity, Cellular/genetics
- Immunity, Innate/genetics
- Immunogenicity, Vaccine
- Pandemics/prevention & control
- Pneumonia, Viral/epidemiology
- Pneumonia, Viral/immunology
- Pneumonia, Viral/prevention & control
- Pneumonia, Viral/virology
- RNA, Viral/isolation & purification
- RNA-Seq/methods
- SARS-CoV-2
- Single-Cell Analysis
- Vaccinology/methods
- Viral Vaccines/administration & dosage
- Viral Vaccines/immunology
Collapse
Affiliation(s)
- Andrés Noé
- The Jenner Institute, University of Oxford, Old Road Campus Research Building, Oxford OX3 7DQ, UK
| | - Tamsin N. Cargill
- Peter Medawar Building for Pathogen Research and Oxford NIHR Biomedical Research Centre, Nuffield Department of Medicine, University of Oxford, South Parks Road, Oxford OX1 3SY, UK
- Translational Gastroenterology Unit, John Radcliffe Hospital, Oxford OX3 9DU, UK
| | - Carolyn M. Nielsen
- The Jenner Institute, University of Oxford, Old Road Campus Research Building, Oxford OX3 7DQ, UK
| | | | - Eleanor Barnes
- Peter Medawar Building for Pathogen Research and Oxford NIHR Biomedical Research Centre, Nuffield Department of Medicine, University of Oxford, South Parks Road, Oxford OX1 3SY, UK
- Translational Gastroenterology Unit, John Radcliffe Hospital, Oxford OX3 9DU, UK
| |
Collapse
|
8
|
Kaushik D, Dhingra S, Patil MT, Piplani S, Khanna V, Honda-Okubo Y, Li L, Fung J, Sakala IG, Salunke DB, Petrovsky N. BBIQ, a pure TLR7 agonist, is an effective influenza vaccine adjuvant. Hum Vaccin Immunother 2020; 16:1989-1996. [PMID: 32298200 PMCID: PMC7482670 DOI: 10.1080/21645515.2019.1710409] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
Better adjuvants are needed for vaccines against seasonal influenza. TLR7 agonists are potent activators of innate immune responses and thereby may be promising adjuvants. Among the imidazoquinoline compounds, 1-benzyl-2-butyl-1H-imidazo[4,5-c]quinolin-4-amine (BBIQ) was reported to be a highly active TLR7 agonist but has remained relatively unexplored because of its commercial unavailability. Indeed, in silico molecular modeling studies predicted that BBIQ had a higher TLR7 docking score and binding free energy than imiquimod, the gold standard TLR7 agonist. To circumvent the availability issue, we developed an improved and higher yield method to synthesize BBIQ. Testing BBIQ on human and mouse TLR7 reporter cell lines confirmed it to be TLR7 specific with significantly higher potency than imiquimod. To test its adjuvant potential, BBIQ or imiquimod were admixed with recombinant influenza hemagglutinin protein and administered to mice as two intramuscular immunizations 2 weeks apart. Serum anti-influenza IgG responses assessed by ELISA 2 weeks after the second immunization confirmed that the mice that received vaccine admixed with BBIQ had significantly higher anti-influenza IgG1 and IgG2c responses than mice immunized with antigen alone or admixed with imiquimod. This confirmed BBIQ to be a TLR7-specific adjuvant able to enhance humoral immune responses.
Collapse
Affiliation(s)
- Deepender Kaushik
- Department of Chemistry and Centre of Advanced Studies in Chemistry, Panjab University , Chandigarh, India
| | - Simran Dhingra
- Department of Chemistry and Centre of Advanced Studies in Chemistry, Panjab University , Chandigarh, India
| | - Madhuri T Patil
- Department of Chemistry, Mehr Chand Mahajan DAV College for Women , Chandigarh, India
| | - Sakshi Piplani
- Vaxine Pty Ltd , Warradale, Australia.,College of Medicine and Public Health, Flinders University , Adelaide, Australia
| | - Varun Khanna
- Vaxine Pty Ltd , Warradale, Australia.,College of Medicine and Public Health, Flinders University , Adelaide, Australia
| | - Yoshikazu Honda-Okubo
- Vaxine Pty Ltd , Warradale, Australia.,College of Medicine and Public Health, Flinders University , Adelaide, Australia
| | - Lei Li
- Vaxine Pty Ltd , Warradale, Australia.,College of Medicine and Public Health, Flinders University , Adelaide, Australia
| | | | - Isaac G Sakala
- Vaxine Pty Ltd , Warradale, Australia.,College of Medicine and Public Health, Flinders University , Adelaide, Australia
| | - Deepak B Salunke
- Department of Chemistry and Centre of Advanced Studies in Chemistry, Panjab University , Chandigarh, India.,National Interdisciplinary Centre of Vaccine, Immunotherapeutics and Antimicrobials (NICOVIA), Panjab University , Chandigarh, India
| | - Nikolai Petrovsky
- Vaxine Pty Ltd , Warradale, Australia.,College of Medicine and Public Health, Flinders University , Adelaide, Australia
| |
Collapse
|
9
|
Hu Z, Banothu J, Beesu M, Gustafson CJ, Brush MJH, Trautman KL, Salyer ACD, Pathakumari B, David SA. Identification of Human Toll-like Receptor 2-Agonistic Activity in Dihydropyridine-Quinolone Carboxamides. ACS Med Chem Lett 2019; 10:132-136. [PMID: 30655960 PMCID: PMC6331173 DOI: 10.1021/acsmedchemlett.8b00540] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2018] [Accepted: 12/20/2018] [Indexed: 12/30/2022] Open
Abstract
Using a multiplexed, reporter gene-based, high-throughput screen, we identified 9-fluoro-7-hydroxy-3-methyl-5-oxo-N-(pyridin-3-ylmethyl)-2,3-dihydro-1H,5H-pyrido[3,2,1-ij]quinoline-6-carboxamide as a TLR2 agonist. Preliminary structure-activity relationship studies on the carboxamide moiety led to the identification of analogues that induce chemokines and cytokines in a TLR2-dependent manner. These results represent new leads for the development of vaccine adjuvants.
Collapse
Affiliation(s)
| | | | | | - Collin J. Gustafson
- Department of Medicinal Chemistry, University of Minnesota, Sixth Street SE, Minneapolis, Minnesota 55455, United States
| | - Michael J. H. Brush
- Department of Medicinal Chemistry, University of Minnesota, Sixth Street SE, Minneapolis, Minnesota 55455, United States
| | - Kathryn L. Trautman
- Department of Medicinal Chemistry, University of Minnesota, Sixth Street SE, Minneapolis, Minnesota 55455, United States
| | - Alex C. D. Salyer
- Department of Medicinal Chemistry, University of Minnesota, Sixth Street SE, Minneapolis, Minnesota 55455, United States
| | - Balaji Pathakumari
- Department of Medicinal Chemistry, University of Minnesota, Sixth Street SE, Minneapolis, Minnesota 55455, United States
| | - Sunil A. David
- Department of Medicinal Chemistry, University of Minnesota, Sixth Street SE, Minneapolis, Minnesota 55455, United States
| |
Collapse
|